Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-040247
Filing Date
2025-04-28
Accepted
2025-04-28 16:36:07
Documents
5

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2512660d7_defa14a.htm DEFA14A 16346
2 GRAPHIC tm2512660d7_defa14aimg01.jpg GRAPHIC 141982
3 GRAPHIC tm2512660d7_defa14aimg02.jpg GRAPHIC 111228
4 GRAPHIC tm2512660d7_defa14aimg03.jpg GRAPHIC 178695
5 GRAPHIC tm2512660d7_defa14aimg04.jpg GRAPHIC 138738
  Complete submission text file 0001104659-25-040247.txt   796873
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36598 | Film No.: 25880991
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)